Bacopa Cognitive Performance Randomized Trial Evidence Table

Structured evidence table for Bacopa Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Bacopa Cognitive Performance Randomized TrialBacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Cognitive Performance Randomized TrialThe cohort predominantly comprises men (53/60, 88.3%), individuals with at least a high school education (47/60, 78.3%), and participants at elevated risk for cognitive decline.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Cognitive Performance Randomized TrialBackground Amnestic mild cognitive impairment (aMCI) represents a transitional stage between normal aging and Alzheimer disease (AD), where early intervention is critical for preserving cognition and delaying or preventing progression to dementia.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Cognitive Performance Randomized TrialDue to the limited availability of curative pharmacological treatments, there is growing interest in traditional and indigenous medicinal interventions, such as Bacopa monnieri (Linn.) or Brahmi, a widely used Ayurvedic nootropic herb.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Cognitive Performance Randomized TrialNew evidence shows that the gut–brain axis is a crucial modulator: intestinal dysbiosis and increased gut permeability may allow bacterial components (including lipopolysaccharide, LPS) and other metabolites to enter the circulation, triggering systemic inflammation and microglial activation in the brain.4Olajide Abosede Temitope (2026)Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
Bacopa Cognitive Performance Randomized TrialIn addition, the oxygen radical antioxidant capacity (ORAC) assay revealed free radical scavenging capacity of 1.17 ± 0.01 µM TE/mg extract.C,D also shows the kinetic fluorescence decay curves of fluorescein and the net area under the curve (AUC), which also gives additional evidence on the antioxidant potential of the extract.4Olajide Abosede Temitope (2026)Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
Bacopa Cognitive Performance Randomized TrialIn contrast, spontaneous alternation behavior, an indicator of working memory, was slightly reduced in the BME group (60.38 ± 6.05%) compared with the LPS (69.46 ± 8.53%), representing a 0.87% decrease, although this difference was not statistically significant (> 0.05;D).4Olajide Abosede Temitope (2026)Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
Bacopa Cognitive Performance Randomized Trial1 2 3 4 Dementia is a neurodegenerative syndrome, a progressive condition characterized by memory loss as well as other cognitive impairments that significantly affect daily activities and quality of life [].4Olajide Abosede Temitope (2026)Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
topicBacopa Cognitive Performance Randomized Trial
claimBacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Cognitive Performance Randomized Trial
claimThe cohort predominantly comprises men (53/60, 88.3%), individuals with at least a high school education (47/60, 78.3%), and participants at elevated risk for cognitive decline.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Cognitive Performance Randomized Trial
claimBackground Amnestic mild cognitive impairment (aMCI) represents a transitional stage between normal aging and Alzheimer disease (AD), where early intervention is critical for preserving cognition and delaying or preventing progression to dementia.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Cognitive Performance Randomized Trial
claimDue to the limited availability of curative pharmacological treatments, there is growing interest in traditional and indigenous medicinal interventions, such as Bacopa monnieri (Linn.) or Brahmi, a widely used Ayurvedic nootropic herb.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Cognitive Performance Randomized Trial
claimNew evidence shows that the gut–brain axis is a crucial modulator: intestinal dysbiosis and increased gut permeability may allow bacterial components (including lipopolysaccharide, LPS) and other metabolites to enter the circulation, triggering systemic inflammation and microglial activation in the brain.
evidence level4
citationOlajide Abosede Temitope (2026)
sourcePhytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
topicBacopa Cognitive Performance Randomized Trial
claimIn addition, the oxygen radical antioxidant capacity (ORAC) assay revealed free radical scavenging capacity of 1.17 ± 0.01 µM TE/mg extract.C,D also shows the kinetic fluorescence decay curves of fluorescein and the net area under the curve (AUC), which also gives additional evidence on the antioxidant potential of the extract.
evidence level4
citationOlajide Abosede Temitope (2026)
sourcePhytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
topicBacopa Cognitive Performance Randomized Trial
claimIn contrast, spontaneous alternation behavior, an indicator of working memory, was slightly reduced in the BME group (60.38 ± 6.05%) compared with the LPS (69.46 ± 8.53%), representing a 0.87% decrease, although this difference was not statistically significant (> 0.05;D).
evidence level4
citationOlajide Abosede Temitope (2026)
sourcePhytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model
topicBacopa Cognitive Performance Randomized Trial
claim1 2 3 4 Dementia is a neurodegenerative syndrome, a progressive condition characterized by memory loss as well as other cognitive impairments that significantly affect daily activities and quality of life [].
evidence level4
citationOlajide Abosede Temitope (2026)
sourcePhytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model

Source documents

  1. Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
  2. Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model